CN119907791A - Tyk2抑制剂的晶型及其用途 - Google Patents

Tyk2抑制剂的晶型及其用途 Download PDF

Info

Publication number
CN119907791A
CN119907791A CN202380052762.3A CN202380052762A CN119907791A CN 119907791 A CN119907791 A CN 119907791A CN 202380052762 A CN202380052762 A CN 202380052762A CN 119907791 A CN119907791 A CN 119907791A
Authority
CN
China
Prior art keywords
crystalline form
powder
ray diffraction
diffraction pattern
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380052762.3A
Other languages
English (en)
Chinese (zh)
Inventor
K·百
T·瑞马虎克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arumis Inc
Original Assignee
Arumis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arumis Inc filed Critical Arumis Inc
Publication of CN119907791A publication Critical patent/CN119907791A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380052762.3A 2022-05-13 2023-05-12 Tyk2抑制剂的晶型及其用途 Pending CN119907791A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263341528P 2022-05-13 2022-05-13
US63/341,528 2022-05-13
US202263405577P 2022-09-12 2022-09-12
US63/405,577 2022-09-12
PCT/US2023/021986 WO2023220338A1 (en) 2022-05-13 2023-05-12 Crystalline forms of a tyk2 inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
CN119907791A true CN119907791A (zh) 2025-04-29

Family

ID=86760338

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380052762.3A Pending CN119907791A (zh) 2022-05-13 2023-05-12 Tyk2抑制剂的晶型及其用途

Country Status (11)

Country Link
EP (1) EP4522602A1 (enExample)
JP (1) JP2025516683A (enExample)
KR (1) KR20250009492A (enExample)
CN (1) CN119907791A (enExample)
AU (1) AU2023269081A1 (enExample)
CA (1) CA3253365A1 (enExample)
CL (1) CL2024003456A1 (enExample)
IL (1) IL317011A (enExample)
MX (1) MX2024014000A (enExample)
TW (1) TW202409007A (enExample)
WO (1) WO2023220338A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202428571A (zh) * 2022-10-10 2024-07-16 美商雅盧米斯公司 Tyk2抑制劑之晶型及其用途
WO2026019902A1 (en) * 2024-07-16 2026-01-22 Alumis Inc. Crystalline forms of a tyk2 inhibitor and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20250048T1 (hr) * 2018-10-22 2025-03-28 Alumis Inc. Inhibitori tyk2 i njihova uporaba

Also Published As

Publication number Publication date
KR20250009492A (ko) 2025-01-17
JP2025516683A (ja) 2025-05-30
CA3253365A1 (en) 2023-11-16
CL2024003456A1 (es) 2025-04-25
AU2023269081A1 (en) 2024-11-28
TW202409007A (zh) 2024-03-01
WO2023220338A1 (en) 2023-11-16
EP4522602A1 (en) 2025-03-19
MX2024014000A (es) 2025-02-10
IL317011A (en) 2025-01-01

Similar Documents

Publication Publication Date Title
EP3216790B1 (en) Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof
AU2015330554B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
TW202409007A (zh) Ｔｙｋ２抑制劑之晶型及其用途
CN120435465A (zh) Tyk2抑制剂的晶型及其用途
WO2015011659A1 (en) Crystalline polymorphic forms of regorafenib and processes for the preparation of polymorph i of regorafenib
WO2016151304A1 (en) Novel polymorphic form x of nilotinib dihydrochloride hydrate
TW201840557A (zh) (s)-[2-氯-4-氟-5-(7-嗎啉-4-基喹唑啉-4-基)苯基]-(6-甲氧基-嗒𠯤-3-基)-甲醇之結晶型
US20260138965A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
CN120603822A (zh) Tyk2抑制剂的结晶形式及其用途
US20240368185A1 (en) Macrocyclic azolopyridines
WO2026019908A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
TW202610624A (zh) Tyk2抑制劑之晶型及其用途
WO2026019902A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
TW202610625A (zh) Tyk2抑制劑之晶型及其用途
TW202334088A (zh) 固體形式
WO2026019900A1 (en) Crystalline forms of a tyk2 inhibitor and uses thereof
MX2008001113A (es) Nueva sal i.
JP2025509759A (ja) レボドーパチロシンの多形
HK1177456A (en) Crystalline forms of 4-methyl-n-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide sulfate and its amorphous form
ME02261B (me) Postupak za pripremu atazanavir bisulfata i novih oblika

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination